Clinical Trials · NCT05313802
A Study of LY3502970 in Healthy Overweight and Obese Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 72
- Start date
- May 2022
- Locations
- 3 sites, United States
- Primary endpoint
- Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration